

Disclosure of movement of 1% or more in substantial holding
or change in nature of relevant interest, or both

Sections 277 and 278, Financial Markets Conduct Act 2013

Note: This form must be completed in accordance with the instructions at the end of the form.

To *New Zealand Stock Exchange & Australian Stock Exchange*
and

To *Fisher & Paykel Healthcare Corp.*

Relevant event being disclosed: a movement of 1% or more in the substantial holding

Date of relevant event: *28 July 2020*

Date this disclosure made: *29 July 2020*

Date last disclosure made: *29 July 2020*

Substantial product holder(s) giving disclosure

Full name(s): *The Capital Group Companies, Inc.*

Summary of substantial holding

Class of quoted voting products: Ordinary Shares (FPH)

Summary for *The Capital Group Companies, Inc.*

For **this** disclosure,—

- (a) total number held in class: *30,810,713*
- (b) total in class: *574,902,659*
- (c) total percentage held in class: *5.3592%*

For **last** disclosure,—

- (a) total number held in class: *37,000,052*
- (b) total in class: *573,995,023*
- (c) total percentage held in class: *6.4460%*

Details of transactions and events giving rise to relevant event

Details of the transactions or other events requiring disclosure: On *28 July 2020*, a total of *-* 1,171,555 shares were sold on-market. See details below.

Asset Description	Activity	Transaction Type	Currency	Price	Shares
FISHER & PAYKEL HEALTHCARE CORP	24-Jul-20	Sell	NZD	35.1300	1,137,915
FISHER & PAYKEL HEALTHCARE CORP	24-Jul-20	Sell	NZD	35.4638	33,640

Details after relevant event

Details for *The Capital Group Companies, Inc.*

The Capital Group Companies, Inc. ("CGC") is the parent company of Capital Research and Management Company ("CRMC"). CRMC is a U.S.-based investment management company that manages the American Funds family of mutual funds. CRMC manages equity assets for various investment companies through three divisions, Capital Research Global Investors, Capital International Investors and Capital World Investors. CRMC in turn is the parent company of Capital Group International, Inc. ("CGII"), which in turn is the parent company of five investment management companies ("CGII management companies"): Capital Guardian Trust Company, Capital International, Inc., Capital International Limited, Capital International Sàrl and Capital International K.K. The CGII management companies primarily serve as investment managers to institutional clients.

Neither CGC nor any of its affiliates own shares of your company for its own account. Rather, the shares reported on this Notification are owned by accounts under the discretionary investment management of one or more of the investment management companies described above.

Nature of relevant interest(s): Non-beneficial owner of securities

For that relevant interest,—

- (a) number held in class: 30,810,713
- (b) percentage held in class: 5.3592%
- (c) current registered holder(s):

Nominee Name	Sum of Shares Held
H.S.B.C. Bank P.L.C. London	29,182
JP Morgan Bank London	55,631
JP Morgan Bank Luxembourg	5,840
JPMorgan Chase Bank	16,149,549
Northern Trust Company Chicago	104,298
Northern Trust Company London	9,587
State Street Bank North Quincy	13,609,974
State Street Trust Canada	801,000
The Bank of New York Mellon	45,652
Total Shares Held	30,810,713

- (d) registered holder(s) once transfers are registered: *unknown*

For a derivative relevant interest, also—

- (a) type of derivative: *not applicable*
- (b) details of derivative: *not applicable*
- (c) parties to the derivative: *not applicable*

- (d) if the substantial product holder is not a party to the derivative, the nature of the relevant interest in the derivative: *not applicable*

Additional information

Address(es) of substantial product holder(s): 333 South Hope Street, 55th Floor, Los Angeles, California, 90071, USA

Contact details: Danielle Harris, Telephone #: ++213.615.0469, E-mail: GRGroup@capgroup.com.

Certification

I, *Danielle Harris*, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.